Company Overview - Zelluna ASA is focused on pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, aiming to deliver transformative therapies for advanced solid cancers globally [1][3] - The company’s TCR-NK platform is designed to provide a unique mechanism of action with broad cancer detection capabilities, addressing the diversity of tumors and overcoming scaling limitations of current cell therapies [3] Event Announcement - An Investor Science and Strategy Forum will be held on 17 September 2025 in Oslo, featuring a panel discussion and open Q&A session [1][2] - The event will include prominent figures such as Dr. Namir Hassan, CEO of Zelluna, and Prof. Bent Jakobsen, a pioneer in TCR therapy for cancer [1] Event Details - Date and Time: 17 September 2025, from 11:30 to 13:00 CET, with lunch served [2] - Venue: Meeting Room 4, Hotel Continental, Stortingsgata 24/26, Oslo [2] - Registration is required, and spaces are limited, with a confirmation deadline of 15 September 2025 [3]

Core Viewpoint - Zelluna is advancing its pioneering allogeneic T-cell receptor-based natural killer (TCR-NK) therapies for cancer treatment, with a focus on achieving clinical readiness and regulatory approvals in the near future [1][5]. Financial Highlights - Total operating expenses for Q2 2025 were MNOK 38.4, with a year-to-date total of MNOK 67.8 [6]. - The total loss for Q2 2025 was MNOK 37.5, bringing the year-to-date loss to MNOK 66.0 [6]. - Net negative cash flow from operations in Q2 2025 was MNOK 59.4, with a net decrease in cash and cash equivalents of MNOK 59.0 during the same period [6]. - As of 30 June 2025, cash and cash equivalents stood at MNOK 76.0, providing a financial runway into Q2 2026, slightly shortened due to one-off costs related to TCR-NK manufacturing development [6]. Business Development - Zelluna is on track for IND/CTA submission in the second half of 2025 and aims to initiate its first-in-human trial in the first half of 2026 [6]. - The company has broadened its regulatory engagement, receiving positive FDA pre-IND feedback in Q2 2024 and submitting a scientific advice briefing package to the UK MHRA in July 2025 [6]. - GMP manufacturing of clinical material commenced in July 2025, enabling the production of hundreds of doses from a single batch [6]. Product Pipeline - The lead program targets MAGE-A4 with "off-the-shelf" TCR-NK therapies for various solid cancers, with additional products in the pipeline [7].

Core Viewpoint - Zelluna is set to present its second quarter 2025 results via a live webcast on August 20, 2025, focusing on its innovative allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment [1]. Group 1 - The webcast will be accessible through a link on Zelluna's website at 09:00 CET on the presentation date [1]. - The report and presentation materials will be available on the company website starting from 07:00 CET on the same day [2]. - Attendees will have the opportunity to post questions during the webcast presentation [1]. Group 2 - For further inquiries, contact information for the CEO and CFO of Zelluna is provided, including email addresses and phone numbers [2].

Core Points - Zelluna ASA has authorized the issuance of new share options to employees and board members as part of a long-term incentive program approved by the General Meeting on April 29, 2025 [1] - A total of 1,634,000 share options have been distributed, representing 8.0% of the outstanding shares, with the combined total from previous and current programs at 8.7% [2] - Each option allows the acquisition of one share at an exercise price of NOK 13.34, based on the volume-weighted average price over the last 30 days [4] Employee Vesting Schedule - For employees, 33% of the options will vest after one year, another 33% after two years, and the final 33% after three years, contingent on continued employment [3] - Board members will have all options vest after one year [3] Option Grants to Executives - CEO Namir Hassan has been granted 550,000 options, CFO Hans Vassgård Eid 175,000 options, COO Anders Holm 145,000 options, Head of Research Luise Weigand 145,000 options, and Head of CMC Emilie Gauthy 80,000 options [4][5] - Other executives and board members have also received options, with specific allocations detailed [5][6]

Group 1 - Inven2 AS, a major shareholder in Zelluna ASA, transferred 120,796 shares to two inventors as per a pre-existing private agreement [1] - After the transaction, Inven2 AS holds 2,207,033 shares in Zelluna ASA, which represents 10.79% of the company's outstanding shares [1]

Group 1 - Zelluna ASA has issued 227,096 new shares as part of a resolution by its Board of Directors to set off an option exercise fee [1] - The new share capital of Zelluna ASA is now registered at NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1 [1] Group 2 - Zelluna ASA aims to provide transformative treatments for advanced solid cancers through innovative "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies [2] - The TCR-NK platform is designed to offer broad cancer detection capabilities, addressing the diversity of tumors and overcoming scaling limitations of current cell therapies [2] - The lead program targets MAGE-A4 and is the world's first "off the shelf" TCR-NK therapy for various solid cancers, with additional products in the pipeline [2] - The management team consists of biotech entrepreneurs with extensive experience in the discovery and clinical development of TCR and cell-based therapies [2]

Core Points - Zelluna ASA's Annual General Meeting authorized the Board of Directors to issue new shares at a subscription price of NOK 26 to settle an option exercise fee of EUR 500,000 to Inven2 [1] - The Board has resolved to issue 227,096 new shares to Inven2 in exchange for the aforementioned amount [1] Company Overview - Zelluna ASA aims to provide transformative treatments for advanced solid cancers in a safe and cost-efficient manner globally [2] - The company focuses on developing "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies, which offer a unique mechanism of action for broad cancer detection [2] - The lead program targets MAGE-A4 with the world's first "off the shelf" TCR-NK therapy for various solid cancers, with additional products in the pipeline [2] - The management team consists of biotech entrepreneurs with extensive experience in the discovery and clinical development of TCR and cell-based therapies [2]

Core Viewpoint - Zelluna ASA, a company focused on allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, announced its first quarter 2025 results, highlighting significant advancements in its manufacturing process and financial performance [1][2]. Financial Update - Total operating expenses for Q1 2025 were MNOK 22.2 [5]. - The net negative cash flow from operations was MNOK 36.0 [5]. - Proceeds from equity issuance amounted to MNOK 51.7, while net cash acquired from the business combination was MNOK 92.3, leading to a net increase in cash and cash equivalents of MNOK 108.0 during Q1 2025 [5]. - Cash and cash equivalents stood at MNOK 135.3 as of March 31, 2025 [5]. - A reverse share split was executed on March 31, 2025, resulting in 20,227,066 outstanding shares, each with a par value of NOK 1 [5]. Business Development - Zelluna successfully completed a business combination with Ultimovacs ASA and Zelluna Immunotherapy AS, along with a private placement that raised gross proceeds of MNOK 51.7 [5]. - The company has developed, scaled, and automated its proprietary manufacturing process for TCR-NK cell therapies, which allows for the production of hundreds of doses from a single batch, enhancing scalability and cost efficiency [5][6]. - The lead program targets MAGE-A4 for the treatment of various solid cancers, marking a significant innovation in the TCR-NK therapeutic field [6].

Core Viewpoint - Zelluna is set to present its first quarter 2025 results via a webcast on May 8, 2025, focusing on its innovative T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment [1] Group 1 - The webcast will be accessible live on the company's website at 09:00 CET on May 8, 2025 [1] - The presentation and report will be available on the Zelluna website from 07:00 CET on the same day [2] - Questions can be submitted during the presentation through the webcast [1]

Oslo, April 29, 2025: Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s website. For further information, please see www.zelluna.com or contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASAEmail: at@radforsk.noPhone: +47 982 06 826 Namir Hassan, CEO, Zelluna ASAEmail: namir.hassan@zelluna.comPhone: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASAEmail: ha ...